Á lódáil...
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
Sunitinib is a tyrosine kinase inhibitor (TKI) used in treatment of metastatic renal cell carcinoma (mRCC), gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. One of the most common side effects related to sunitinib is hypothyroidism. Recent trials suggest correlation between the...
Na minha lista:
| Foilsithe in: | Med Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Springer US
2017
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5366170/ https://ncbi.nlm.nih.gov/pubmed/28343336 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-017-0928-z |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|